TENAX THERAPEUTICS, INC.
For the period ended Dec 31, 2024. Filed Mar 25, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 25, 2025
TENX$1.69+3.7%Stored close · as of Nov 6, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
CONSOLIDATED BALANCE SHEETS
(Amounts in thousands, except share and per share data)
| December 31, 2024 | December 31, 2023 | |
|---|---|---|
| ASSETS | ||
| Current assets | ||
| Cash and cash equivalents | $94,851 | $9,792 |
| Prepaid expenses | 1,771 | 1,640 |
| Other current assets | 64 | 252 |
| Total current assets | 96,686 | 11,684 |
| Other assets | - | 1 |
| Total assets | $96,686 | $11,685 |
| LIABILITIES AND STOCKHOLDERS’ EQUITY | ||
| Current liabilities | ||
| Accounts payable | $3,157 | $2,073 |
| Accrued liabilities | 1,536 | 1,013 |
| Note payable | - | 501 |
| Total current liabilities | 4,693 | 3,587 |
| Total liabilities | 4,693 | 3,587 |
| Stockholders' equity | ||
| Preferred stock, undesignated, authorized 4,818,654 shares | ||
| Series A Preferred stock, par value $0.0001, issued 5,181,346 shares; outstanding 210, as of December 31, 2024 and December 31, 2023, respectively | - | - |
| Common stock, par value $0.0001 per share; authorized 400,000,000 shares; issued and outstanding 3,420,906 as of December 31, 2024 and 298,281 as of December 31, 2023, respectively | - | - |
| Additional paid-in capital | 406,848 | 305,351 |
| Accumulated deficit | (314,855) | (297,253) |
| Total stockholders’ equity | 91,993 | 8,098 |
| Total liabilities and stockholders' equity | $96,686 | $11,685 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.